• HOME > PRESS ROOM > Media Highlight
    • 16
    • Unhwa registers a patent for an “anti-cancer” wild ginseng Ddobyul product based on plant stem cells.
    • 2013.03.30

    • Unhwa’s President Young-Woo Jin said that his bio-technology company had completed the patent registration for the invention of a medicine for the prevention or treatment of cancer. This medicine includes cambium extracted from active ingredients of wild ginseng plant stem cells along with other types of Ginseng.
       
      An Unhwa executive said ”In 2005, we successfully isolated and cultivated plant stem cells and this became the Ddobyul trademark. This anti-cancer patent registration is recognition of the development of the world’s first original product made from cambium extracted from wild ginseng for use as an anti-cancer pharmaceutical product”
       
      This research provided Unhwa with the opportunity to sign an MOU (Memorandum of Understanding) agreement last year with Chung-Ang University Hospital, which they hope will spur the development and discovery of new natural anti-cancer drug products.
       
      This patent registration is Unhwa’s second in recent times. Last October, Unhwa registered a patent for a yew stem cell product.
       
      Unhwa used analysis methods authorized by the USP (U.S Pharmacopeia) to compare farmed Asian Ginseng and wild ginseng stem cells. The results showed that wild ginseng stem cells contained Rg1, Re, Rb1, Rc, Rb2 and Rd.  Specifically, for Rb1, the content was greater than that of the Asian Ginseng CRM (Certified Reference Material).
      *Asian Ginseng CRM is registered as a USP Standard substance.
       
      Also, due to the nature of undifferentiated wild ginseng stem cells, It’s complex components, composed of acidic polysaccharides, peptides, proteins besides ginsenoside would be likely to create a synergistic effect.
       
      Currently, Seoul National University’s College of Pharmacy, the Korean Institute of Science and Technology (KIST), the University of Maryland’s School of Medicine in the U.S and other research institutes within Korea and abroad are working to identify the mechanism and efficacy of the active components.
       
      Meanwhile, during the last year, Unhwa was selected by the Korean Ministry of Knowledge Economy as a company acting as a global leader in the natural product drug discovery development area. The aim of this research product is to create a product for the U.S market that can treat AIDS (Acquired Immune Deficiency Syndrome) and to develop other natural drug products. Also, on March 7th 2013, Unhwa successfully completed the Pre-IND meeting stage with the U.S FDA and next they plan to perform multi-national clinical trials in Korea, the U.S and Ghana.